MINDway: A Phase Ib/II Dose Optimization Study to Assess Safety and Pharmacokinetics of Tafasitamab plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

被引：0
|
作者：
Greil, Richard [1 ,2 ]
Kopeckova, Katerina [3 ,4 ]
Arcaini, Luca [5 ,6 ]
Amin, Aasim [7 ]
de Graaf, Katrien [8 ]
Jegg, Anna-Maria [7 ]
机构：
[1] Paracelsus Med Univ, Salzburg, Austria
[2] Salzburg Canc Res Inst Ctr Clin Canc & Immunol Tr, Canc Cluster, Salzburg, Austria
[3] Charles Univ Prague, Fac Med 2, Dept Oncol, Prague, Czech Republic
[4] Motol Univ Hosp, Prague, Czech Republic
[5] Fdn IRCCS Policlin San Matteo, Div Hematol, Pavia, Italy
[6] Univ Pavia, Dept Mol Med, Pavia, Italy
[7] MorphoSys AG, Clin Dev, Planegg, Germany
[8] MorphoSys AG, Clin Pharmacol, Planegg, Germany
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
ABCL; CD19; tafasitamab; lenalidomide; DLBCL; MINDway; Trial-in-Progress;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ABCL-052
引用
收藏
页码：S356 / S356
页数：1
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS ANALYSIS OF TAFASITAMAB IN COMBINATION WITH LENALIDOMIDE FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA IN GREECE
    Karaiskou, M.
    Avgitidou, A.
    Vostitsanou, Z.
    Batsi, M.
    Bungey, G.
    Prawitz, T.
    Peter, B.
    Stafylas, P.
    VALUE IN HEALTH, 2023, 26 (12) : S151 - S151
  • [32] A Phase Ib, Open-Label, Randomized Study to Assess Safety and Preliminary Efficacy of Tafasitamab (MOR208) or Tafasitamab plus Lenalidomide in Addition to R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Analysis of the Safety Run-in Phase
    Belada, David
    Nowakowski, Grzegorz S.
    Burgues, Juan Miguel Bergua
    Andre, Marc
    Kopeckova, Katerina
    Stevens, Don A.
    Trneny, Marek
    Persona, Ernesto Perez
    Pichler, Petra
    Klopfer, Pia
    Brackertz, Bettina
    Lohrmann, Emanuel
    Lahiry, Anirban
    Shah, Neha
    Fingerle-Rowson, Gunter
    Brugger, Wolfram
    Burke, John M.
    BLOOD, 2020, 136
  • [33] Combination of Atezolizumab and Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results From a Phase Ib Study
    Palomba, Maria Lia
    Cartron, Guillaume
    Popplewell, Leslie
    Ribrag, Vincent
    Westin, Jason
    Huw, Ling-Yuh
    Agarwal, Shefali
    Shivhare, Mahesh
    Hong, Wan-Jen
    Raval, Aparna
    Chang, Alice C.
    Penuel, Elicia
    Morschhauser, Franck
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (07): : 504 - 512
  • [34] A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Kambhampati, Swetha
    Kallam, Avyakta
    Borogovac, Azra
    Chen, Lu
    Puverel, Sandrine
    Johnson, Jennifer
    Melgar, Ivana
    Baird, John H.
    Danilov, Alexey
    Godfrey, James
    Khan, Niloufer
    Mei, Matthew
    Phillips, Tycel J. J.
    Siddiqi, Tanya
    Shouse, Geoffrey
    Zain, Jasmine
    Kwak, Larry W.
    Rosen, Steven T.
    Forman, Stephen J.
    Song, Joo Y.
    Herrera, Alex F.
    Budde, Elizabeth
    BLOOD, 2024, 144 : 17421 - 17422
  • [35] Real-World Experience Using Tafasitamab Plus Lenalidomide and/or Loncastuximab Tesirine in a Predominately Hispanic Population with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Latiolais, Heidi
    Horowitz, Justin
    Michalek, Joel
    Duque, Adolfo Enrique Diaz
    BLOOD, 2024, 144 : 7780 - 7781
  • [36] Pharmacokinetics and Pharmacodynamics in First-MIND: A Phase Ib, Open-Label, Randomized Study of Tafasitamab ± Lenalidomide plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma
    Belada, David
    Kopeckova, Katerina
    Burgues, Juan Miguel Bergua
    Stevens, Don
    Nowakowski, Grzegorz S.
    Waldron-Lynch, Maeve
    Hadar, Nira
    Weirather, Johannes
    Laessig, Charlotte
    Blair, Derek
    Dreyling, Martin
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S352 - S352
  • [37] Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
    Mondello, Patrizia
    Steiner, Normann
    Willenbacher, Wolfgang
    Ferrero, Simone
    Ghione, Paola
    Marabese, Alessandra
    Pitini, Vincenzo
    Cuzzocrea, Salvatore
    Mian, Michael
    ONCOLOGIST, 2016, 21 (09): : 1107 - 1112
  • [38] Combination of Lenalidomide and Rituximab in Elderly Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Phase 2 Trial
    Zinzani, Pier Luigi
    Pellegrini, Cinzia
    Gandolfi, Letizia
    Stefoni, Vittorio
    Quirini, Federica
    Derenzini, Enrico
    Broccoli, Alessandro
    Argnani, Lisa
    Pileri, Stefano
    Baccarani, Michele
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2011, 11 (06): : 462 - 466
  • [39] Targeted Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Tafasitamab in Context
    Abdulhaq, Haifaa
    Hwang, Andrew
    Mahmood, Omar
    ONCOTARGETS AND THERAPY, 2023, 16 : 617 - 629
  • [40] A MULTICENTER PHASE II STUDY OF BENDAMUSTINE WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Kim, W. S.
    Ando, K.
    Niitsu, N.
    Ogura, M.
    Takahashi, N.
    Uike, N.
    Eom, H. Seok
    Chae, Y. S.
    Tobinai, K.
    Terauchi, T.
    Tateishi, U.
    Tatsumi, M.
    Suh, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 94 - 94
12345